These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 8588250

  • 1. [Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity].
    Gutsalo AE, Varetskaia TV, Kozulina EP, Papaian LP.
    Ukr Biokhim Zh (1978); 1995; 67(1):3-13. PubMed ID: 8588250
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS.
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [Abstract] [Full Text] [Related]

  • 7. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
    Yoshioka A.
    Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
    [No Abstract] [Full Text] [Related]

  • 8. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS, Ganz PR, Perkins H, Rosborough D, Rock G.
    Thromb Haemost; 1990 Jun 28; 63(3):392-402. PubMed ID: 2119525
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C, Fischer AM, Schlegel N, Rothschild C, Torchet MF, Dautzenberg MD, Aujard Y.
    Nouv Rev Fr Hematol (1978); 1988 Jun 28; 30(4):225-7. PubMed ID: 3143100
    [Abstract] [Full Text] [Related]

  • 13. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB.
    Haematologica; 2003 Jun 28; 88(6):EREP02. PubMed ID: 12826528
    [Abstract] [Full Text] [Related]

  • 14. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G, Bykowska K, Ludwicka A, Letowska M, Wegrzynowicz Z, Sablinski J, Lopaciuk S.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990 Jun 28; 117(4):565-70. PubMed ID: 1714861
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D, Kreuz W, Auerswald G, Auberger K, Rabenau H, Gürtler L, Roggendorf M.
    Thromb Haemost; 1995 Apr 28; 73(4):736-7. PubMed ID: 7495095
    [No Abstract] [Full Text] [Related]

  • 17. Cryoprecipitate therapy in haemophilia.
    Forbes CD, Hunter J, Barr RD, Davidson JF, Short DW, McDonald GA, McNicol GP, Wallace J, Douglas AS.
    Scott Med J; 1969 Jan 28; 14(1):1-9. PubMed ID: 5304824
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the in vivo survival of human factor VIII with and without von Willebrand factor in the hemophilic dog.
    Fay PJ, Cavallaro C, Marder VJ, Pancham N, Fournel MA, Schroeder DD.
    Thromb Res; 1986 Feb 01; 41(3):425-9. PubMed ID: 3085273
    [No Abstract] [Full Text] [Related]

  • 19. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
    Aufderheide WM, Skinner SF, Kaneko JJ.
    Am J Vet Res; 1975 Apr 01; 36(4 Pt.1):367-70. PubMed ID: 1124873
    [Abstract] [Full Text] [Related]

  • 20. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F, Stein P.
    Z Gesamte Inn Med; 1982 Oct 01; 37(19):641-4. PubMed ID: 6817530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.